Feng Chi Biotech (ROCO:6744) LT-Debt-to-Total-Asset: 0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6744 Feng Chi Biotech Corp ROCO:6744
82 GF Score
Price NT$15.80
GF Value NT$20.82
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Feng Chi Biotech LT-Debt-to-Total-Asset?

Feng Chi Biotech ROCO:6744 +1.94% 82 LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus rates ROCO:6744 with a GF Score™ of 82/100 and a GF Value™ of NT$20.82 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Feng Chi Biotech's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.01.

Feng Chi Biotech's long-term debt to total assets ratio declined from Dec. 2024 (0.02) to Dec. 2025 (0.01). It may suggest that Feng Chi Biotech is progressively becoming less dependent on debt to grow their business.

Feng Chi Biotech  (ROCO:6744) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Feng Chi Biotech LT-Debt-to-Total-Asset Related Terms

Feng Chi Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Feng Chi Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech LT-Debt-to-Total-Asset Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.04 0.03 0.02 0.01

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.02 0.01 0.01
ROCO:6744
82GF Score
Feng Chi Biotech Corp ROCO:6744
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Feng Chi Biotech LT-Debt-to-Total-Asset Calculation

Feng Chi Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=2.631/287.911
=0.01

Feng Chi Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=2.631/287.911
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Feng Chi Biotech (ROCO:6744) has a LT-Debt-to-Total-Asset of 0.01 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Feng Chi Biotech and its competitors.
Is Feng Chi Biotech's LT-Debt-to-Total-Asset too high?
Feng Chi Biotech's current LT-Debt-to-Total-Asset is 0.01. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Feng Chi Biotech's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Feng Chi Biotech and its competitors. Feng Chi Biotech's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.82, compared to a current price of NT$15.80 — trading 24.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current LT-Debt-to-Total-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?

Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued. The current stock price of NT$15.80 is trading 24.1% below its estimated GF Value™ of NT$20.82. GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.

Key valuation signals for ROCO:6744:

  • LT-Debt-to-Total-Asset: 0.01
  • GF Value™: NT$20.82 vs. price of NT$15.80 (24.1% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Feng Chi Biotech Business Description

Address No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score

Get the complete analysis for ROCO:6744

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.80
Price
NT$20.82
GF Value